About our research

Dendritic cell-based therapy:

Dendritic cell-based cryoimmunotherapy (CryoIT) has been tested in the first Phase I clinical trial at Department of Urology, Haukeland University Hospital. 18 patients with metastatic and castration-resistant prostate cancer were treated with good safety and encouraging efficacy data during follow-up.

A revised CryoIT protocol will be used for the next stage CryoIT clinical trial in preparation. Robust production of more potent therapeutic GMP-grade dendritic cells, new biomarker development and further development of a preclinical patient tissue explant and xenograft model are ongoing.

Drug discovery and development:

Currently the IL6/STAT3 and WNT/beta-catenin pathways, and IDO-1 regulation are focused, both in prostate cancer cells and immune cells.  Both FDA-approved drug panels and novel phytochemically isolated drug panels have been screened. Several patent applications and publications have resulted from this approach.